Overview

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines.
Phase:
Phase 2
Details
Lead Sponsor:
Sunovion Respiratory Development Inc.